The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.
Donna Niedzwiecki
No relevant relationships to disclose
Wendy Frankel
No relevant relationships to disclose
Alan Paul Venook
No relevant relationships to disclose
Xing Ye
No relevant relationships to disclose
Paula N. Friedman
No relevant relationships to disclose
Richard M. Goldberg
No relevant relationships to disclose
Robert J. Mayer
No relevant relationships to disclose
Thomas Anthony Colacchio
No relevant relationships to disclose
Richard D. Kennedy
Employment or Leadership Position - Almac Diagnostics
Timothy Davison
Employment or Leadership Position - Almac Diagnostics
Eamonn J. O'Brien
Employment or Leadership Position - Almac Diagnostics
Jude Mulligan
Employment or Leadership Position - Almac Diagnostics
Patrick G. Johnston
Stock Ownership - Almac Diagnostics
D. Paul Harkin
Employment or Leadership Position - Almac Diagnostics
Stock Ownership - Almac Diagnostics
Richard L. Schilsky
No relevant relationships to disclose
Monica M. Bertagnolli
No relevant relationships to disclose
Federico Innocenti
No relevant relationships to disclose